Elsevier

Journal of Autoimmunity

Volume 103, September 2019, 102287
Journal of Autoimmunity

Obstetric and neonatal complications among women with autoimmune disease

https://doi.org/10.1016/j.jaut.2019.05.015Get rights and content

Highlights

  • Across a spectrum of autoimmune disease, risk for adverse obstetric and neonatal outcomes is high.

  • Preterm birth and cesarean delivery risks were notably higher for women with autoimmune disease.

  • Clinical indications for cesarean delivery were similar across types of autoimmune diseases.

  • Type 1 diabetes mellitus conferred the highest risk for most poor obstetric and neonatal outcomes.

Abstract

Background

The impact of autoimmune diseases on pregnancy remains understudied on a population level. Examination of obstetric and neonatal outcomes among women with autoimmune disease and their infants can provide important insights for clinical management.

Methods

Autoimmune diseases and outcomes were identified using medical records. Cesarean delivery, preterm birth, preeclampsia, small for gestational age (SGA), neonatal intensive care (NICU) admission, neonatal respiratory distress syndrome (RDS), and perinatal mortality risk was assessed. Poisson regression with robust standard errors estimated relative risks (RR) and 95% confidence intervals (95% CI) with adjustment for maternal characteristics and other chronic conditions.

Results

Women with T1DM were at increased risk for nearly all outcomes including RDS (RR: 3.62; 95% CI: 2.84, 4.62), perinatal mortality (RR: 2.35; 95% CI: 1.12, 4.91), cesarean delivery (RR: 2.16; 95% CI: 2.02, 2.32) and preterm birth (RR: 3.52; 95% CI: 3.17, 3.91). Women with SLE also had higher risk for preterm delivery (RR: 2.90; 95% CI: 2.42, 3.48) and RDS (RR:2.99; 95% CI: 1.99, 4.51) as did women with Crohn's (cesarean delivery RR:1.31, 95% CI: 1.08, 1.60; preterm delivery RR: 1.84, 95% CI: 1.37, 2.49. RA increased risk for SGA (RR:1.66; 95% CI: 1.08, 2.55).

Conclusion(s)

Despite the heterogeneity in autoimmune diseases, we observed elevated preterm birth risk for most women with autoimmune disease. SLE and T1DM appeared to confer increased risk for a wide range of adverse outcomes.

Introduction

The worldwide estimated cumulative prevalence of autoimmune disease is approximately 5% [1], and increasing [2]. Approximately 66% of autoimmune diseases have a mean age of onset less than 50 years [1], and 80% of autoimmune cases in the U.S. occur among women [3,4]. It is important to understand the effect autoimmune diseases have on pregnant women and their infants.

The physiologic regulation of inflammation during pregnancy plays an important function in obstetric and neonatal outcomes. Inflammation, an immune-mediated response, assists in implantation and placentation early in pregnancy. Inflammation also promotes parturition and placental expulsion [5]. Later in gestation, pro-inflammatory processes at the maternal/fetal interface due to infection or placental abruption may lead to preterm birth, preeclampsia, and other adverse outcomes [6]. Research into the etiology of these outcomes is warranted. Inflammation is a key feature of autoimmune disease [3,4,7]. However, the population-level impact of autoimmune diseases on pregnancy remains understudied. Our previous work found women with asthma or thyroid disease had an increased risk for poor obstetric and infant outcomes [[8], [9], [10]], yet not all cases of asthma or thyroid disease are autoimmune. The underlying biologic mechanisms linking autoimmune disease and increased risk of adverse obstetric and neonatal outcomes are not well understood yet may result from overlapping physiologic adaptations necessary for pregnancy [11,12], their disease states [[13], [14], [15], [16], [17], [18], [19], [20]], the presence of autoantibodies or medications [21,22] required for management during pregnancy [17,21,23,24].

A challenge in studying the association of autoimmune diseases with obstetric and neonatal outcomes is the rarity of both. Research conducted to date is largely among homogenous populations outside the U.S. [[14], [15], [16], [17],22,[25], [26], [27], [28], [29], [30], [31], [32], [33], [34], [35], [36], [37], [38], [39], [40], [41]]. Studies conducted among U.S. populations are often limited by small sample sizes [21,30,40] or focused on a specific autoimmune disease and lacked detailed data on multiple obstetric and infant outcomes [34,42,43].

Cesarean delivery and preterm delivery are most frequently examined in the existing literature. Women with type 1 diabetes mellitus (T1DM) [12,32,41,44], systemic lupus erythematosus (SLE) [[45], [46], [47], [48]], Crohn's disease [[49], [50], [51], [52]] or rheumatoid arthritis (RA) [22,53,54] are reported to be at increased risk for cesarean delivery but evidence among women with multiple sclerosis (MS) is mixed. Two population-based studies found women with MS had approximately 40% higher risk for cesarean delivery [27,28], while two other population-based studies [26,55] and two small case-control studies [25,56] found no increased risk. In addition, prior studies did not explore the indications or timing of cesarean deliveries (prelabor or intrapartum).

Similarly, evidence among women with T1DM [14,44], SLE [18,57], Crohn's [52,58,59] or RA [18,31,34] suggests increased risk of preterm birth while reports of preterm birth risk among women with MS are inconsistent. Two population-based studies report an increased preterm birth risk among women with MS [27,28], and four other studies report no increased risk [25,26,29,30]. No data are available regarding precursors of preterm birth or spontaneous versus induced deliveries among women with autoimmune disease.

Evidence for other prevalent complications associated with autoimmune disease is also inconclusive. For example, among women with RA, four studies report an increased risk of small for gestational age (SGA) [21,31,32,60], while four studies report no increased risk of SGA [16,22,33,34]. Evidence regarding neonatal intensive care unit (NICU) admission is also sparse with mixed results [[15], [16], [17],22,33,[35], [36], [37], [38], [39], [40]]. For certain autoimmune diseases like T1DM, and Crohn's disease, studies are limited and none have been conducted among US populations [14,15,39,41].

Using a nationwide US cohort, we aimed to provide a more comprehensive description of the obstetric and neonatal risks among women with autoimmune disease and their infants. To better understand obstetric and neonatal risks associated with maternal autoimmune disease, we examined women in the Consortium on Safe Labor (CSL) diagnosed with T1DM, SLE, Crohn's, MS, or RA. These diseases are heterogeneous and their target tissues vary (pancreatic β-cells for T1DM [61]; various tissues including musculoskeletal, renal, and central nervous system for SLE [62]; bowel in Crohn's [63]; the nervous system in MS [64]; and musculoskeletal system in RA [65]).

Section snippets

Consortium on Safe Labor

The CSL was a U.S. retrospective cohort study from 2002 to 2008 that abstracted labor and delivery information from electronic medical records from 19 U.S. hospitals. Data extracted for deliveries at 23 gestational weeks or later (n = 228,438) included: maternal sociodemographic characteristics, medical, reproductive and prenatal history, labor and delivery summaries, postpartum and newborn data [66]. For these analyses, we excluded multifetal pregnancies (n = 5,063, 2.2%), mothers with thyroid

Prevalence of autoimmune diseases

The prevalence of autoimmune diseases (cases per 1000 pregnancies) for the CSL population by demographic variables are presented in Table 1.

Black women had the highest rates of T1DM (2.9/1000) and SLE (1.3/1000), while white women had the highest rates of Crohn's (1.4/1000), MS (1/1000), and RA (0.8/1000). Women with private insurance had the highest rates of SLE (1.1/1000), Crohn's (1.1/1000), and MS (0.9/1000). Women with public insurance had the highest rate of T1DM (2.9/1000). Rates of

Discussion

Despite advances in management of autoimmune disease that aid women in fulfilling family plans, pregnant women with autoimmune diseases continue to experience increased risk of poor obstetric and neonatal outcomes. We found the risk for cesarean delivery after spontaneous or induced labor was similar among women with T1DM. However, the increased risk of overall cesarean delivery for women with SLE, Crohn's, MS or RA may have been due to increased risk of cesarean delivery after spontaneous

Conflicts of interest

Authors report no conflict of interest.

Source of funding

This research was supported by the Intramural Research Program of the National Institutes of Health, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), including funding for the Consortium on Safe Labor (Contract No. HHSN267200603425C) and the Air Quality and Reproductive Health Study (Contract No. HHSN275200800002I, Task Order No. HHSN27500008). This paper has been cleared for publication by the NICHD but the funding source had no role in the design,

References (80)

  • O. Stephansson et al.

    Crohn's disease is a risk factor for preterm birth

    Clin. Gastroenterol. Hepatol.

    (2010)
  • A. Lateef et al.

    Managing lupus patients during pregnancy

    Best Pract. Res. Clin. Rheumatol.

    (2013)
  • D.C. Baumgart et al.

    Inflammatory bowel disease: clinical aspects and established and evolving therapies

    The Lancet

    (2007)
  • J.A. Hollenbach et al.

    The immunogenetics of multiple sclerosis: a comprehensive review

    J. Autoimmun.

    (2015)
  • S. Yasmeen et al.

    Accuracy of obstetric diagnoses and procedures in hospital discharge data

    Am. J. Obstet. Gynecol.

    (2006)
  • A. Lerner et al.

    The world incidence and prevalence of autoimmune diseases is increasing

    Int. J. Celiac Dis.

    (2015)
  • G. Mor et al.

    Inflammation and pregnancy: the role of the immune system at the implantation site

    Ann. N. Y. Acad. Sci.

    (2011)
  • J.R. Challis et al.

    Inflammation and pregnancy

    Reprod. Sci.

    (2009)
  • I.R. Mackay et al.

    The nature of autoimmune disease

    Semin. Liver Dis.

    (1997)
  • P. Mendola et al.

    Obstetric complications among US women with asthma

    Am. J. Obstet. Gynecol.

    (2013)
  • P. Mendola et al.

    Neonatal health of infants born to mothers with asthma

    J. Allergy Clin. Immunol.

    (2014)
  • T. Männistö et al.

    Thyroid diseases and adverse pregnancy outcomes in a contemporary US cohort

    J. Clin. Endocrinol. Metab.

    (2013)
  • M. Persson et al.

    Birth size distribution in 3,705 infants born to mothers with type 1 diabetes: a population-based study

    Diabetes Care

    (2011)
  • J. Lepercq et al.

    Factors associated with preterm delivery in women with type 1 diabetes

    A cohort study

    (2004)
  • T. Cundy et al.

    Hypertensive disorders of pregnancy in women with Type 1 and Type 2 diabetes

    Diabet. Med. : a journal of the British Diabetic Association

    (2002)
  • U.I. Hanson et al.

    Outcome of pregnancies complicated by type 1 insulin-dependent diabetes in Sweden: acute pregnancy complications, neonatal mortality and morbidity

    Am. J. Perinatol.

    (1993)
  • H.-S. Kim et al.

    Maternal and neonatal outcomes in Korean women with type 1 and type 2 diabetes

    Diabetes & Metabolism Journal

    (2015)
  • C. Barnabe et al.

    Canadian pregnancy outcomes in rheumatoid arthritis and systemic lupus erythematosus

    International Journal of Rheumatology

    (2011)
  • S. Phansenee et al.

    Pregnancy outcomes among women with systemic lupus erythematosus: a retrospective cohort study from Thailand

    Lupus

    (2017)
  • J.F. Simard et al.

    Early-onset preeclampsia in lupus pregnancy

    Paediatr. Perinat. Epidemiol.

    (2017)
  • B. Bharti et al.

    Disease severity and pregnancy outcomes in women with rheumatoid arthritis: results from the organization of teratology information specialists autoimmune diseases in pregnancy project

    J. Rheumatol.

    (2015)
  • M. Wallenius et al.

    Rheumatoid arthritis and outcomes in first and subsequent births based on data from a national birth registry

    Acta Obstet. Gynecol. Scand.

    (2014)
  • A. Spinillo et al.

    The impact of unrecognized autoimmune rheumatic diseases on the incidence of preeclampsia and fetal growth restriction: a longitudinal cohort study

    BMC Pregnancy Childbirth

    (2016)
  • B. Konecna et al.

    Immune activation by nucleic acids: a role in pregnancy complications

    Scand. J. Immunol.

    (2018)
  • E. Yalcin Serenat et al.

    Maternal and perinatal outcomes in pregnancies with multiple sclerosis: a case-control study

    J. Perinat. Med.

    (2017)
  • M.L. van der Kop et al.

    Neonatal and delivery outcomes in women with multiple sclerosis

    Ann. Neurol.

    (2011)
  • Y.H. Chen et al.

    Does multiple sclerosis increase risk of adverse pregnancy outcomes? A population-based study

    Multiple Sclerosis Journal

    (2009)
  • J. Dahl et al.

    Pregnancy, delivery, and birth outcome in women with multiple sclerosis

    Neurology

    (2005)
  • M. Nørgaard et al.

    Rheumatoid arthritis and birth outcomes: a Danish and Swedish nationwide prevalence study

    J. Intern. Med.

    (2010)
  • H.-C. Lin et al.

    Increased risk of adverse pregnancy outcomes in women with rheumatoid arthritis: a nationwide population-based study

    Ann. Rheum. Dis.

    (2010)
  • Cited by (0)

    View full text